Home » Stocks » ERYP

Erytech Pharma S.A. (ERYP)

Stock Price: $12.28 USD 0.27 (2.23%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
After-hours: $12.00 -0.28 (-2.28%) Jan 20, 7:17 PM
Market Cap 253.57M
Revenue (ttm) 5.94M
Net Income (ttm) -70.40M
Shares Out 17.94M
EPS (ttm) -2.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $12.28
Previous Close $12.01
Change ($) 0.27
Change (%) 2.23%
Day's Open 12.86
Day's Range 11.21 - 12.93
Day's Volume 7,560
52-Week Range 3.85 - 12.93

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

Zacks Investment Research - 1 week ago

ERYTECH Pharma (ERYP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

GlobeNewsWire - 2 weeks ago

Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating ...

GlobeNewsWire - 2 weeks ago

ERYTECH to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

GlobeNewsWire - 1 month ago

LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by enc...

GlobeNewsWire - 1 month ago

LYON, France and CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by enc...

GlobeNewsWire - 1 month ago

LYON, France, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

GlobeNewsWire - 1 month ago

W ebcast today, Monday, December 7 at 4:00 pm CET/10:00 am ET

GlobeNewsWire - 1 month ago

Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ET Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ET

GlobeNewsWire - 2 months ago

LYON, France and CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced t o day that its CEO, Gil Beyen, will present an update at the Jefferie...

Seeking Alpha - 2 months ago

ERYTECH Pharma's (ERYP) CEO Gil Beyen on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Conference call and webcast on Friday, November 6 at 2:30 pm CET/8:30 am ET

GlobeNewsWire - 2 months ago

LYON, France and CAMBRIDGE, Mass. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by en...

GlobeNewsWire - 2 months ago

Article 223-16 of general regulation of French Autorité des Marchés Financiers

GlobeNewsWire - 2 months ago

LYON, France and CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by enc...

GlobeNewsWire - 2 months ago

LYON, France, Oct. 29, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulati...

GlobeNewsWire - 2 months ago

LYON, France and CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by enc...

Seeking Alpha - 2 months ago

ERYTECH is progressing a phase 3 trial in pancreatic cancer. The drug, reformulated L-asparaginase, has known anti-cancer properties but its safety profile needs to be good.

GlobeNewsWire - 3 months ago

Article 223-16 of general regulation of French Autorité des Marchés Financiers

Seeking Alpha - 3 months ago

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

LYON, France, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsu...

GlobeNewsWire - 4 months ago

LYON, France, Sept. 16, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsula...

GlobeNewsWire - 4 months ago

LYON, France and CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by...

GlobeNewsWire - 4 months ago

LYON, France, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

Seeking Alpha - 4 months ago

Erytech is a company with a promising novel method targeting the large cancer market with unmet needs.

GlobeNewsWire - 5 months ago

LYON, France, Aug. 06, 2020 (GLOBE NEWSWIRE) --   Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

GlobeNewsWire - 6 months ago

LYON, France, July 10, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

GlobeNewsWire - 6 months ago

LYON, France and CAMBRIDGE, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2020 Annual General Meeting was held in Lyon on Frid...

GlobeNewsWire - 6 months ago

Agreement with Alpha Blue Ocean and European High Growth Opportunities Securitization Fund for the issuance of zero-coupon convertible notes with share warrants attached Agreement with Alpha B...

GlobeNewsWire - 7 months ago

LYON, France, June 09, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

GlobeNewsWire - 7 months ago

LYON, France and CAMBRIDGE, Mass., June 09, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by ...

Zacks Investment Research - 7 months ago

Erytech Pharma SA Sponsored ADR (ERYP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 8 months ago

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

LYON, France, May 07, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

GlobeNewsWire - 8 months ago

Conference call and webcast on Thursday, May 7 at 2:30 pm CET/8:30 am ET

GlobeNewsWire - 8 months ago

LYON, France and CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by en...

GlobeNewsWire - 8 months ago

LYON, France and CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by...

GlobeNewsWire - 8 months ago

LYON, France and CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing red blood cell-based ca...

GlobeNewsWire - 9 months ago

LYON, France, April 20, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing red blood cell-based cancer therapeutics, to...

GlobeNewsWire - 9 months ago

LYON, France, April 06, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

GlobeNewsWire - 10 months ago

LYON, France and CAMBRIDGE, Mass., March 19, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by...

Seeking Alpha - 10 months ago

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

LYON, France and CAMBRIDGE, Mass. , March 16, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies b...

GlobeNewsWire - 10 months ago

Article 223-16 of general regulation of French Autorité des Marchés Financiers Article 223-16 of general regulation of French Autorité des Marchés Financiers

GlobeNewsWire - 11 months ago

Second European source of donor red blood cells secured in preparation for expanded production of red blood cell-based therapeutics

GlobeNewsWire - 11 months ago

Article 223-16 of general regulation of French Autorité des Marchés Financiers Article 223-16 of general regulation of French Autorité des Marchés Financiers

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor ERYTECH Pharma.

GlobeNewsWire - 1 year ago

Article 223-16 of general regulation of French Autorité des Marchés Financiers Article 223-16 of general regulation of French Autorité des Marchés Financiers

GlobeNewsWire - 1 year ago

Article 223-16 of general regulation of French Autorité des Marchés Financiers Article 223-16 of general regulation of French Autorité des Marchés Financiers

GlobeNewsWire - 1 year ago

First asparaginase-based therapy to demonstrate clinical efficacy and safety in solid tumors First asparaginase-based therapy to demonstrate clinical efficacy and safety in solid tumors

About ERYP

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ER... [Read more...]

Industry
Biotechnology
Founded
2004
CEO
Gil Beyen
Employees
217
Stock Exchange
NASDAQ
Ticker Symbol
ERYP
Full Company Profile

Financial Performance

In 2019, Erytech Pharma's revenue was 5.28 million, an increase of 18.80% compared to the previous year's 4.45 million. Losses were -62.66 million, 63.9% more than in 2018.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Erytech Pharma stock is "Strong Buy." The 12-month stock price forecast is 17.89, which is an increase of 45.68% from the latest price.

Price Target
$17.89
(45.68% upside)
Analyst Consensus: Strong Buy